Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Evolocumab Gains Expanded Indication for Primary Prevention

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

TCTMD’s Top 10 Most Popular Stories for December 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

December 29, 2021

TCTMD’s Top 10 Most Popular Stories for March 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

April 02, 2021

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.